Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company Founding Year: 1896
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: COVID-19
Phase 3: Hepatitis C, Chronic
Phase 2: Hepatitis C, Chronic|Hepatitis A|Hepatitis C
Phase 1: Healthy Volunteers|Hepatitis A|Hepatitis C, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04952207 |
C-DIAMOND | N/A |
Unknown status |
Hepatitis C, Chronic|Hepatitis A |
2021-07-31 |
2023-07-04 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR2000031734 |
ChiCTR2000031734 | N/A |
Recruiting |
COVID-19|Pneumonia |
2020-05-29 |
|||
ChiCTR2000030259 |
ChiCTR2000030259 | N/A |
Recruiting |
COVID-19|Pneumonia |
2020-04-30 |
|||
NCT03288636 |
ASC-ASC16-I-CTP-02 | P1 |
Completed |
Healthy Volunteers |
2017-09-14 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT03020134 |
ASC162002 | P1 |
Completed |
Healthy Volunteers |
2016-08-22 |
18% |
2019-03-21 |
Treatments |
NCT03019991 |
ASC08201501 | P1 |
Completed |
Healthy Volunteers |
2015-11-01 |
2019-03-21 |
Treatments |
|
NCT01654211 |
NP28297 | P1 |
Completed |
Healthy Volunteers |
2012-11-01 |
2019-03-19 |
Treatments |
|
NCT01588002 |
NP28103 | P1 |
Completed |
Healthy Volunteers |
2012-06-01 |
2019-03-19 |
Treatments |
|
NCT01592318 |
NP28136 | P1 |
Completed |
Healthy Volunteers |
2012-06-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT01592305 |
NP28104 | P1 |
Completed |
Healthy Volunteers |
2012-06-01 |
2019-03-19 |
Treatments |
|
NCT01519336 |
NP28089 | P1 |
Completed |
Healthy Volunteers |
2012-03-01 |
2019-03-19 |
||
NCT03020004 |
ASC08201502 | P2 |
Completed |
Hepatitis C, Chronic |
2016-11-01 |
2019-03-21 |
Treatments |
|
NCT03020095 |
ASC162001 | P2 |
Completed |
Hepatitis C, Chronic |
2016-08-01 |
2019-03-21 |
Treatments |
|
NCT01749150 |
YV28218 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2015-02-01 |
2019-03-19 |
Treatments |
|
NCT01579019 |
NV22877 | P2 |
Withdrawn |
Hepatitis C, Chronic |
2014-03-01 |
2019-03-19 |
Treatments |
|
2012-000638-21 |
ANNAPURNA | P2 |
Completed |
Hepatitis C, Chronic |
2013-11-28 |
2022-03-13 |
Treatments |
|
NCT01483742 |
NP27946 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2013-09-01 |
2019-03-19 |
Treatments |
|
2011-004129-28 |
2011-004129-28 | P2 |
Completed |
Hepatitis C, Chronic |
2013-08-28 |
2022-03-13 |
Treatments |
|
2010-019585-90 |
Matterhorn | P2 |
Completed |
Hepatitis C, Chronic |
2013-01-25 |
2022-03-13 |
Treatments |
|
NCT01331850 |
WV21913 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2013-01-01 |
2019-03-19 |
Treatments |
|
NCT01220947 |
NV22776 | P2 |
Completed |
Hepatitis C, Chronic |
2012-12-01 |
2019-03-19 |
Treatments |
|
2010-019584-10 |
2010-019584-10 | P2 |
Completed |
Hepatitis C |
2012-07-08 |
2022-03-13 |
Treatments |
|
NCT03362814 |
ASC-ASC16-II/III-CTP-1-01 | P3 |
Completed |
Hepatitis C, Chronic |
2018-12-12 |
28% |
2020-07-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03020082 |
ASC08201503 | P3 |
Completed |
Hepatitis C, Chronic |
2017-05-01 |
2021-03-24 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT04345276 |
ASC-CTP-HS-01 | P4 |
Completed |
COVID-19 |
2020-04-15 |
2020-06-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |